Effects of formoterol and salmeterol on cytokine release from monocyte-derived macrophages

The European Respiratory Journal
L E DonnellyP J Barnes

Abstract

Pulmonary macrophages are a target for inhaled therapies. Combinations of long-acting beta(2)-agonists (LABA) and glucocorticosteroids have been developed for asthma and chronic obstructive pulmonary disease (COPD). This study examined two LABA, salmeterol and formoterol, and the glucocorticosteroid, budesonide, on cytokine release from monocyte-derived macrophages (MDM) to determine whether anti-inflammatory effects observed in patients are due to inhibition of macrophages. MDM were incubated in the absence or presence of LABA or budesonide prior to stimulation with lipopolysaccharide (LPS). Tumour necrosis factor (TNF)-alpha, granulocyte macrophage-colony stimulating factor (GM-CSF) and CXC chemokine ligand (CXCL)8 were measured by ELISA. Formoterol and salmeterol inhibited LPS-stimulated release of TNF-alpha (mean effective concentration (EC(50)) 2.4+/-1.8 and 3.5+/-2.7 nM, respectively; n = 11-16), GM-CSF (EC(50) 24.6+/-2.1 and 52.4+/-40.8 nM, respectively, n = 11-12) but not CXCL8 from LPS-stimulated MDM. Budesonide inhibited release of all three cytokines (EC(50) TNF-alpha: 1.2+/-0.4 nM; GM-CSF: 0.4+/-0.2 nM; CXCL8: 0.4+/-0.1 nM; n = 3-4). Formoterol but not salmeterol elevated cAMP in these cells. These effects were atte...Continue Reading

Citations

Feb 10, 2012·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Markus BosmannPeter A Ward
Nov 29, 2013·Drug Design, Development and Therapy·Annette J TheronRonald Anderson
Nov 21, 2012·The American Journal of Medicine·Sanjay SethiStephen Rennard
Apr 27, 2013·Respirology : Official Journal of the Asian Pacific Society of Respirology·Jochen J RüdigerMichael Roth
Aug 22, 2015·Postgraduate Medicine·Reynold A Panettieri
Apr 1, 2015·British Journal of Pharmacology·Eva WexPhilippe Devillier
Sep 23, 2014·The Lancet. Respiratory Medicine·Lydia FinneyPatrick Mallia
Nov 12, 2016·European Journal of Pharmacology·Sharonjit K GillPeter T Peachell
Jun 22, 2017·Developmental and Comparative Immunology·Elodie BacouBlandine Lieubeau
Aug 26, 2011·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Yue-Ping GuoWen-Zhi Li
Dec 20, 2017·The Journal of Immunology : Official Journal of the American Association of Immunologists·Janice A LayhadiSamuel J Fountain
Jul 4, 2018·American Journal of Physiology. Endocrinology and Metabolism·Ana Isabel MartínAsunción López-Calderón
Feb 12, 2014·The Journal of Pharmacology and Experimental Therapeutics·Stacey L TannheimerMichael Salmon
Jul 28, 2016·British Journal of Pharmacology·Sharonjit K GillPeter T Peachell
Dec 19, 2018·American Journal of Respiratory and Critical Care Medicine·Lydia J FinneyJadwiga A Wedzicha
Apr 27, 2018·Frontiers in Immunology·Didem AğaçJ David Farrar
Dec 20, 2019·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·Yang Yie SioFook Tim Chew
Nov 22, 2020·Seminars in Immunopathology·Drashya Sharma, J David Farrar
Feb 20, 2021·Scientific Reports·Miranda P WeenSandra J Hodge
Apr 22, 2021·Respiratory Research·R SinghUNKNOWN COPDMAP consortium
Jun 10, 2021·Molecular Omics·Amanda L PetersonDarren J Creek
Aug 7, 2021·International Journal of Chronic Obstructive Pulmonary Disease·Jonathan R Baker, Louise E Donnelly

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.